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The importance of the induction of virus neutralizing antibodies to provide protection against foot-and-mouth disease virus
(FMDV) infection is well established. However, recent studies with recombinant adenovirus expressing the precursor
polypeptide of the viral capsid (P1) indicate that cattle inoculated with this recombinant vector developed partial protection
against FMDV infection, in the absence of a detectable specific humoral response. Other viral vectors have been widely used
to induce protective immunity against many pathogens, and it has been reported that the use of different vectors for priming
and boosting injections can provide a synergistic effect on this response. In this work, we determined the immunogenicity
of two recombinant viruses (adenovirus and vaccinia) expressing P1-FMDV, administered either individually or sequentially,
and the protection that they induced against FMDV challenge in pigs. A double immunization with the adeno-P1 virus was the
most effective strategy at inducing protective immunity. In contrast to previous reports, the use of two different vectors for
priming and boosting did not show a synergistic effect on the protection induced against FMD. Interestingly, immunized pigs
developed FMDV-specific T cell responses but not detectable antibodies. Thus, the protection observed was likely to be
mediated by a cellular immune response.
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Foot and mouth disease (FMD) continues to have a
onsiderable incidence in many countries. It is caused
y a picornavirus of the Aphtovirus genus (FMDV) that
ffects cloven-hoofed animals, with cattle and swine
eing the most important target species (Pereira, 1981).
n natural infections, the main route of virus entry is the
espiratory tract and initial virus multiplication usually
akes place in the pharynx epithelium (Burrows et al.,
981). Within 24–48 h after infection, viremia starts and
he virus enters the bloodstream and spreads to different
issues producing vesicles in the mouth and feet. Exper-
mentally, the virus can be inoculated intradermally into
he tongue or in the hooves. Vesicles appear within 10 to
2 h after inoculation at the point of the infection, fever
nd viremia occur within 20 to 24 h, and secondary
esicles appear within 2 to 4 days. The acute phase of
he disease is associated with viremia and fever, lasts
bout 1 week, and declines gradually, coinciding with the
ppearance of a strong humoral response (Sutmoller
nd McVicar, 1976; Bachrach, 1977). Protection against
MD has been generally related to high levels of circu-
1 Current address: AZTI-SIMA, Departamento Sanidad Animal,
/Bereaga 1, E-48160 Derio (Bizkaia), Spain.
2 To whom correspondence and reprint requests should be ad-
aressed. Fax: 34 91 6202247. E-mail: ley@inia.es.
129ating neutralizing antibodies (Van Bekkum, 1969). How-
ver, it is now established that a T cell response is a
equisite for effective immunity against the viral infection
Collen, 1994; Becker, 1994). Both CD41 and CD81 anti-
iral responses have been detected following FMDV in-
ection, although its role in the mechanisms involved in
rotection remains unclear (Sa´iz et al., 1992; Collen,
994; Van Lierop et al., 1995; Childerstone et al., 1999).
onventional vaccines against FMD, made of inactivated
irus, have been shown to provide solid protection, al-
hough of reduced duration (Barteling and Vreeswijk,
991; Woolhouse et al., 1996), which has allowed the
radication of the disease in several countries. These
accines elicit mainly a strong humoral response with
igh titers of antiviral neutralizing antibodies against
ntigenic sites identified on the viral capsid (Brown,
995; Mateu, 1995). This humoral response correlates
ith a solid lymphoproliferative response (Sa´iz et al.,
992; Collen et al., 1990) and with a considerable al-
hough short-lived protection (Barteling and Vreeswijk,
991). However, the spectrum of antiviral immune mech-
nisms induced by these vaccines is limited (Barteling
nd Vreeswijk, 1991). The objective of this study was to
nvestigate the capacity of the precursor capsid polypep-
ide, P1 (containing the four structural proteins VP1–VP4),
f FMDV, expressed by recombinant adenovirus and/or
accinia virus, to induce a protective immune response
gainst FMDV infection in pigs. The results suggest that
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130 SANZ-PARRA ET AL.pecific T cells induced against viral antigens (P1) can
rovide a rapid effector mechanism that partially protects
wine against FMDV challenge.
RESULTS
Many reports have demonstrated that immunization
ith recombinant viruses can elicit humoral and cellular
esponses and confer protection against infections of
ifferent pathogens. Recombinant adenovirus express-
ng the P1 precursor polypeptide of FMDV has been
hown to induce partial protection in cattle (Sanz-Parra
t al., 1999). In this case, anti-FMDV humoral responses
ere not detected in the immunized animals, but the
echanisms involved in the protection were not deter-
ined. On the other hand, immunization with two differ-
nt viral vectors expressing a pathogen antigen has
een shown to produce a synergistic effect on the re-
ponse induced in the animals (Li et al., 1993). Based on
hese data, we designed an experiment aimed at study-
ng the immune response and protection induced in pigs,
y recombinant vaccinia and adenovirus expressing the
1 capsid precursor of FMDV. In addition, we wanted to
etermine whether the combined use of these two viral
ecombinant vectors would enhance the immune re-
ponse.
To perform these analyses, groups of pigs were inoc-
lated, independently or subsequently, with VV-P1 or/and
d5-P1 recombinant viruses, as detailed under Materials
nd Methods. All animals received two doses, at days 1
nd 29, consisting of same immunogen except for group
in which the first dose consisted of Ad5-P1 and the
econd was VV-P1. To determine the protection against
he FMDV infection, all animals were challenged at day
5 with a dose of FMDV known to produce disease and
ypical lesions in pigs.
ntibody responses to FMDV in Ad5-P1-immunized
igs
The production of specific antibodies in pigs inocu-
ated with the different recombinant viruses was mea-
ured by ELISA in samples of sera collected after two
mmunizations and 13 days after the challenge with
MDV. As shown in Fig. 1a, none of the animals inocu-
ated with the recombinant vectors expressing the P1
eveloped detectable levels of anti-FMDV antibodies be-
ore challenge, whereas all pigs showed consistent anti-
d5 and/or anti-V V responses. However, all animals
ere seroconverted after challenge (Fig. 1b), developing
nti-FMDV titers that were similar in two of the groups
mmunized with recombinant viruses (B, C), and in those
mmunized with control vectors (D, E) or not immunized
F). Antibody titers were slightly lower in group A, which
eceived two immunizations of Ad5-P1, possibly due to
he higher level of protection induced in these animals.
hese results indicate that anti-FMDV antibodies were gost likely induced by the virus challenge rather than by
he P1 expressed by the recombinant vectors used to
mmunize the pigs.
ellular immune response to FMDV in immunized
igs
The ability of the recombinant viral vectors expressing
1 to induce specific T cell responses against FMDV
as determined by lymphoproliferation assays. PBMCs
ere collected from blood samples of animals inocu-
ated with the recombinant vectors before and after
MDV challenge. As shown in Figs. 1c and 1d, significant
pecific lymphoproliferation against C-S8 FMDV was ob-
erved in T cells from all groups of P1-immunized pigs
nd not in the control animals. Contrary to the antibody
nduction, the T cell response was clearly detected be-
ore FMDV challenge (Fig. 1c). However, the response
as boosted upon viral challenge only in animals inoc-
lated twice with Ad5-P1 (group A) (Fig. 1d). The capacity
f the immune T cells induced by the different immuni-
ations to recognize heterotypic FMDV was also studied.
or this purpose, a type O isolate (O1K) was used as
timulator in the proliferative assays. As shown in Figs.
c and 1d, lymphocytes from some immunized animals
ere also stimulated with this virus before challenge,
nd all of them lymphoproliferated after viral challenge.
rotection of immunized animals against FMDV
nfection
We then determined the ability of the recombinant-P1
iruses to induce protection against FMD. Sixteen days
fter the second immunization, pigs were challenged by
ntradermal injection of 4.5 3 105 PFU of C-S8 FMDV.
linical symptoms were monitored daily by measuring
ectal temperatures and recording the development of
outh and feet lesions. The criteria considered as indic-
tive of protection were the absence, reduction, or delay
f clinical symptoms and pyrexia (.39.5°C).
As shown in Table 1, all groups of pigs developed
yrexia following virus infection. Yet, a reduction of the
uration and a delay of 1 day were observed in the
roups of pigs immunized with VV-P1, with Ad5-P1, or
ith both recombinant viruses expressing P1. The level
f protection conferred by the P1-expressing viruses was
ore evident in the development of clinical signs (vesic-
lar lesions) and the severity of the disease (Table 1). All
ontrol pigs immunized with Ad5-wt, VV-WR, or PBS de-
eloped severe clinical signs: large vesicles in all four
eet and mouth, anorexia, and lameness. These symp-
oms appeared at 48 h postchallenge and remained for
t least 10 days, except in one pig from group F who died
t day 7. Conversely, pigs immunized with VV or Ad5 virus
xpressing P1 showed limited vesicular lesions that ap-
eared at day 4 and were small and not generalized. The
roup showing a higher level of protection was that of
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131FMDV-RECOMBINANT VIRUSES INDUCE PARTIAL PROTECTION IN PIGSnimals immunized twice with Ad5-P1 (group A). These
igs developed small vesicles in only one (A1) or two (A2,
3) feet and disappeared in 2 days. Pigs of groups B and
also showed a significant level of protection: a delay of
t least 2 days in the appearance of vesicles and an
ttenuated severity of lesions. Neither lameness nor an-
rexia was observed in any pig from these P1-immu-
ized groups.
DISCUSSION
We have recently shown that a recombinant vaccinia
irus expressing the precursor polypeptide of FMDV cap-
id proteins (P1) induces an antiviral cellular response in
uinea pigs (Sanz-Parra et al., 1998). In addition, a P1
xpressing recombinant adenovirus was able to confer
artial protection against FMDV challenge in cattle
Sanz-Parra et al., 1999). P1 contains important FMDV B
ell epitopes (Bittle et al., 1982; Strohmaier et al., 1982;
FIG. 1. Immune responses against FMDV, V V, and Ad5 virus induce
ronasally at days 1 and 29, with Ad5-P1 (group A), V V-P1 (group B), Ad
t day 1 and boosted with V V-P1 at day 29. Control pigs (group F) we
mmunization (day 45) and 13 days after challenge with FMDV (day 58) a
f ELISA of sera tested at 1:50 dilution. Data on (c) and (d) represent the
ith FMDV C-S8 or O1K. Error bars represent the standard deviation.rown, 1995; Mateu, 1995; Saiz et al., 1994), as well as T rell epitopes of FMDV (Collen, 1994; Rodriguez et al.,
994; van Lierop et al., 1995). In addition, the P1 polypep-
ide expressed in cells infected with recombinant Ad5-P1
r VV-P1 reacts specifically with anti-FMDV antibodies
Sanz-Parra et al., 1998, 1999).
Previous studies demonstrated that a combined im-
unization with two different recombinant virus express-
ng the same foreign antigen was an effective strategy
or inducing a protective immune response (Li et al.,
993). In these studies, the higher protection was ob-
ained in animals boosted with recombinant VV after
riming with another recombinant virus, but not when the
everse protocol was followed. On the other hand, it has
een reported that recombinant adenovirus was highly
fficient at the induction of an anti-malaria cellular im-
une response (Rodrigues et al., 1997).
Based on these results, in this study we designed an
noculation schedule including both Ad5-P1 and VV-P1
munized pigs. Groups of pigs were immunized subcutaneously and
roup D), or V V WR (group E). Pigs in group C were primed with Ad5-P1
immunized. Blood samples were collected 16 days after the second
essed to obtain PMBC or sera. Data on (a) and (b) represent the results
of triplicates of the uptake of [3H]thymidine (cpm) by PMBS stimulatedd on im
5 wt (g
re not
nd proc
meanecombinant viruses, administrated either independently
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132 SANZ-PARRA ET AL.r sequentially, to investigate the immune response elic-
ted and their ability to induce protection against FMDV
n pigs, another important FMDV host species.
The results obtained here show that a double immu-
ization with recombinant virus expressing the P1
olypeptide of FMDV can elicit an antiviral immune re-
ponse and partially protect pigs against viral challenge.
lthough the number of animals used for this type of
tudy was not sufficient for statistical demonstration, we
hink that the data are consistent with a significant bio-
ogical trend, also found in a similar experiment in cattle
Sanz-Parra et al., 1999), and that the results obtained are
T
Pyrexia and Clinical Symptoms D
Animal Day 2 Day 3
a) Pyrexia
Group A A1 11
(Ad5-P1 1 A2 1
Ad5-P1) A3 11
Group B B1 1
(V V-P1 1 B2 2
V V-P1) B3 11
Group C
(Ad5-P1 1 C1 1
V V-P1) C2 11
Group D D1 1 11
(Ad5-wt) D2 1111 1111
Group E E1 11 11
(V V-WR) E2 111 11
Group F F1 1 11
(no inoculation) F2 11
b) Lesions
Group A A1
(Ad5-P1 1 A2
Ad-P1) A3
Group B B1
(V V-P1 1 B2
V V-P1) B3
Group C
(Ad5-P1 1 C1
V V-P1) C2
Group D D1 111 1111
(Ad5-wt) D2 111 1111
Group E E1 1111 1111
(V V-WR) E2 1111
Group F F1 11 1111
(no inoculation) F2 11 1111
Note. The protocol of immunization and challenge was as described
umber of plus signs. In (a), 1 represents 39–40°C; 11 represents 40–
2°C. In (b) 1 represents mild lesions (one small lesion in one foot); 1
esions generalized in all four feet.ot due to fortuitous animal variation. AIn contrast to other reports, the highest levels of pro-
ection were achieved in animals that received two
oses of Ad5-P1 at days 1 and 29, and we did not
bserve an enhancement by using two different vectors
priming with Ad5 and boosting with VV). A double im-
unization with VV-P1 induced similar levels of protec-
ion to the combined Ad5-P1/VV-P1 immunization.
The analysis of the humoral response against FMDV
evealed that none of the recombinant viruses were able
o induce detectable levels of antiviral antibodies before
hallenge. Interestingly, upon FMDV infection, the levels
f antiviral antibodies in pigs inoculated twice with
d in Pigs after FMDV Challenge
Day 4 Day 5 Day 6 Day 7 Day 8
1 1 1
11
11
11
1 1
111 111
11 11 11 1
11 11 11 1
11 11 1 died died
11 1 11 1 2
11 1 1
11 1
1 1
11 11
1 1 11 11
111 11 11 11
111 1 1 1
111 11 11 11
11 11 11 1
1 11 11 11 1
111 1111 1111 1111 1111
111 1111 1111 1111 1111
111 1111 1111 died died
111 1111 1111 1111 1111
111 1111 1111 1111 1111
111 1111 1111 1111 1111
Materials and Methods. The level of protection is represented by the
11 represents 41–42°C and 1111 represents pyrexia higher than
ns in two feet; 111 lesions in three or four feet; and 1111, severeABLE 1
evelope
1
1
1
1
1
under
41°C, 1
1 lesiod5-P1 were significantly lower than those induced in
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133FMDV-RECOMBINANT VIRUSES INDUCE PARTIAL PROTECTION IN PIGShe other groups (Fig. 1b). This result is consistent with a
educed viral replication and therefore with the higher
evel of protection observed in these animals.
The lack of a detectable humoral response in the pigs
rior to challenge is possibly due to the intracellular
ocation of the FMDV antigens in cells infected with the
ecombinant viruses and corroborates our previous re-
ults observed in other species (Sanz-Parra et al., 1998,
999). However, the cytoplasmic expression of P1 anti-
en may allow the induction of other T cell responses.
In contrast to the lack of humoral response, all the
ecombinant P1-expressing viruses induced significant
MDV-specific proliferative responses of T cells in the
rimed animals. However, in this case, although the
ellular response was lower in the Ad5-P1 pigs before
hallenge, it was highest upon FMDV challenge. These
esults are consistent with the induction of a more effec-
ive protective response in the Ad5-P1 inoculated ani-
als and show that higher levels of clinical protection
orrelate with the strongest T cell proliferative responses
gainst the virus.
These results suggest that the mechanisms of protec-
ion induced in the pigs immunized with the P1-recom-
inant viruses were not mediated by antiviral antibodies.
his is of great interest, because it is generally assumed
hat protection against FMDV infection is afforded mainly
y neutralizing antibodies (Van Bekkum, 1969). However,
lthough the existence of other protective mechanisms
s poorly understood, the induction of both CD41 and
D81 antiviral responses following FMDV infection has
een recently reported (Childerstone et al., 1999). Fur-
hermore, in this study the protection observed was as-
ociated with the induction of a specific cellular immune
esponse against the virus. Thus, these results show that
ecombinant Ad5 and V V expressing the P1 antigen
nduce an antiviral cellular immune response that may
e involved in the mechanisms that confer immunity to
MDV infection.
MATERIALS AND METHODS
Recombinant viruses. The recombinant adenovirus ex-
ressing the P1 polypeptide of FMDV C1 (C-S8) (Ad5-P1)
as constructed as described (Sanz-Parra et al., 1999).
n short, P1 FMDV sequence was inserted into the E3
egion of the Ad5 genome of the intermediate plasmid
FG144K3, which was cotransfected into 293 cells (Gra-
am et al., 1977) together with the plasmid pFG173 (Bett
t al., 1993; Mittal et al., 1993), resulting in the generation
f recombinant Ad5-P1 virus. Wild-type adenovirus 5
Ad5 wt) and recombinant Ad5-P1 virus stocks were
rown and titered in 293 cell cultures as described (Gra-
am and Prevec, 1991). The construction of the recom-
inant vaccinia virus expressing the P1 polypeptide of
MDV (C-S8) isolate (V V-P1), was reported elsewhereSanz-Parra et al., 1998). Vaccinia Western Reserve (VV pR) and VV-P1 were grown and titered by plaque assay
n BSC-1 cells.
FMDV isolates. C-S8 type C1 FMDV isolate was used
or animal challenge. To stimulate T cells in the lympho-
roliferation assays, C-S8 isolate and type O FMDV
O1kb) were used. The viruses were grown in BHK-21
ells and supernatants of infected cells were clarified
nd stored at 270°C. Titers of the viral stocks were
etermined by plaque assay in BHK-21 cells (Domingo et
l., 1980) and are expressed as PFU/ml.
Animal immunization and virus challenge. Groups of
hree pigs (2-month-old Large White 3 Landrace) were
mmunized at days 1 and 29, each time by two routes,
ronasal and subcutaneous, with 109 PFU per route of
V-P1 (group A), Ad5-P1 (group B), Ad5-P1 at day 1 and
V-P1 at day 29 (group C), Ad5 wt (group D), and VV WR
group E). The pigs were challenged intradermally in the
eel bulbs of the right forefoot at day 45 with 4.5 3 105
FU of purified C-S8 FMDV. After challenge, rectal tem-
eratures and clinical signs were monitored daily for 3
eeks. Samples of venous blood were collected at days
, 45, and 78 to determine anti-FMDV, -Ad5, and -VV
ntibody titers in sera and specific antiviral lymphopro-
iferative responses.
Antibody determination. Blood samples were collected
t days 45 (2 weeks after the second immunization) and
8 (13 days after FMDV challenge). Antibody responses
o C-S8 FMDV were measured in serum samples by
LISA as described (Jimenez-Clavero et al., 1998), using
.2 mg of virus per well. Antibody responses to Ad5 were
etermined as above, using 0.2 mg of Ad5 wt virus
approximately 106 PFU) per well. A similar ELISA was
erformed to measure the antibody responses to VV,
sing plates incubated with 0.2 mg of VV WR per well.
ound antibodies were detected by an anti-swine immu-
oglobulin–horseradish peroxidase conjugate (Dako,
enmark). Color was developed with 3,39,5,59-tetrameth-
lbenzidine (Sigma) as chromogenic substrate. Results
re expressed as the absorbance in OD units at 450 nm
f a 1:50 dilution of samples (Day 0 values were sub-
racted).
Lymphoproliferation assays. Proliferation assays of
wine lymphocytes were performed as described (Rodri-
uez et al., 1994). Blood was collected in 5 mM EDTA and
sed immediately for the preparation of peripheral blood
ononuclear cells (PBMC). Proliferation assays were
erformed in 96-well round-bottomed microtiter plates
Nunc). Briefly, 2 3 105 PBMC per well were cultured in
riplicate, in complete RPMI (10% FCS, 50 mM 2-mercap-
oethanol), in the presence of various concentrations of
-S8 or O1K FMDV isolates, ranging from 4 3 10
3 to 2 3
06 PFU, in a final volume 200 ml per well. Cultures
ithout virus were included as control. Cells were incu-
ated at 37°C in a humidified atmosphere containing 5%
O2 for 4 days. Following incubation, each well was
3ulsed with 0.5 mCi of methyl-[ H]thymidine for 18 h. The
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134 SANZ-PARRA ET AL.ells were collected using a cell harvester and the in-
orporation of radioactivity into the DNA was measured
y liquid scintillation in a Microbeta counter (Pharmacia).
esults were expressed as D cpm (mean cpm of stimu-
ated cultures - mean cpm of control cultures).
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